Holdings A/s Novo's Net Worth

$1.51 Billion

Who is Holdings A/s Novo?

Holdings A/s Novo has an estimated net worth of $1.51 Billion. This is based on reported shares across multiple companies, which include ALDER BIOPHARMACEUTICALS INC, Arcellx, Inc., Morphic Holding, Inc., Flexion Therapeutics Inc, REATA PHARMACEUTICALS INC, CoLucid Pharmaceuticals, Inc., ZS Pharma, Inc., Nkarta, Inc., Praxis Precision Medicines, Inc., Apollo Endosurgery, Inc., KalVista Pharmaceuticals, Inc., Inogen Inc, ANAPTYSBIO INC, Milestone Pharmaceuticals Inc., iRhythm Technologies, Inc., Verve Therapeutics, Inc., IO Biotech, Inc., Edgewise Therapeutics, Inc., NEVRO CORP, Mirum Pharmaceuticals, Inc., Ophthotech Corp., Harmony Biosciences Holdings, Inc., Cyteir Therapeutics, Inc., Corvus Pharmaceuticals, Inc., Aligos Therapeutics, Inc., Reneo Pharmaceuticals, Inc., Inozyme Pharma, Inc., Galecto, Inc., Eargo, Inc., Entasis Therapeutics Holdings Inc., Checkmate Pharmaceuticals, Inc., Galera Therapeutics, Inc., Bolt Biotherapeutics, Inc., SPRUCE BIOSCIENCES, INC., HTG MOLECULAR DIAGNOSTICS, INC, Akebia Therapeutics, Inc., MINERVA SURGICAL INC, OTONOMY, INC., Ra Pharmaceuticals, Inc., Disc Medicine, Inc., BIOMIMETIC THERAPEUTICS, INC., and Regado Biosciences Inc.

SEC CIK

Holdings A/s Novo's CIK is 0001388325

Past Insider Trading and Trends

2008 was Holdings A/s Novo's most active year for acquiring shares with 556 total transactions. Holdings A/s Novo's most active month to acquire stocks was the month of April. 2017 was Holdings A/s Novo's most active year for disposing of shares, totalling 50 transactions. Holdings A/s Novo's most active month to dispose stocks was the month of May. 2018 saw Holdings A/s Novo paying a total of $26,347,520.00 for 3,358,313 shares, this is the most they've acquired in one year. In 2016 Holdings A/s Novo cashed out on 11,406,518 shares for a total of $81,298,384.87, their largest year based on trade value.